Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
  • C12N7/02—Recovery or purification
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
  • C12N2750/00011—Details
  • C12N2750/14011—Parvoviridae
  • C12N2750/14311—Parvovirus, e.g. minute virus of mice
  • C12N2750/14351—Methods of production or purification of viral material

Definitions

• Biopharmaceutical products such as monoclonal antibodies, recombinant proteins, vaccines, blood derivatives and animal products carry a risk of transmitting infectious viruses. This is due to source material possibly being intrinsically contaminated with viruses. Additionally, manufacturing processes of
• biopharmaceutical products are susceptible to virus contamination from extrinsic sources. As a result, manufacturers of biopharmaceutical products are required to incorporate sufficient virus clearance steps into their manufacturing processes to ensure that their products are contaminant virus-free. It is a safety and regulatory imperative that manufacturing processes of biopharmaceutical products incorporate these virus clearance steps.
• virus clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential virus contaminants.
• Spiking studies are typically used to evaluate and validate virus clearance steps in a scaled down model of a production-scale process.
• the purity and titer of virus stocks used for virus clearance studies have a significant influence on study outcome.
• the purity and titer of the virus stocks impact how well the scaled down model represents the production-scale process.
• impurities in virus stocks adversely impact the testing of small virus retentive filters used in virus clearance steps.
• the impurities are introduced as a consequence of the impure virus stock used in the validating spiking studies, and are not reflective of typical manufacturing processes on the production-scale process.
• the test unit e.g., a filter
• fouls prematurely exhibits altered fouling conditions, and adversely affects fluid passage through the virus filter. Consequently, the true throughput capacity of the filter is
• the production-scale unit is oversized to compensate for the apparent lower performance of the unit in the validation study. This increases production costs.
• this underestimates the actual capacity of the test unit to clear virus in the production process since the titer of the virus stock often determines the maximum possible concentration of virus spiked into the test material which, when all virus is effectively cleared by the test unit, limits the virus clearance claim of the test unit.
• virus stocks e.g., for use in spiking studies
• virus stocks of as high titer as possible are desirable, since the volume of virus spike that can be added to a test system is limited by Regulatory Guidelines.
• Current methods lack the capacity to produce virus stocks of high titer and high purity.
• the virus can be any suitable virus as desired, such as a mammalian virus, or a bacteriophage.
• virus stocks are suitable for use, for example, as a virus spike in an evaluation and/or validation study.
• one embodiment of the invention is a method of preparing a high purity virus.
• the method comprises the sequential steps of obtaining a viral sample prepared under low protein conditions, concentrating the viral sample in a suitable buffer, and precipitating the virus in the viral sample, such that the precipitated virus is a high purity virus.
• the high purity virus is a high purity virus stock solution.
• the method of preparing a high purity virus comprises chromatographic polishing.
• the method of preparing a high purity virus comprises the sequential steps of obtaining a viral sample prepared under low protein conditions, concentrating the viral sample in a suitable buffer, precipitating the virus in the viral sample, and chromatographic polishing the precipitated virus, thereby producing a high purity virus.
• the high purity virus is a high purity virus stock solution.
• the high purity virus or high purity virus stock solution has a protein concentration of less than 50 ug/ml. In another embodiment, the high purity virus or high purity virus stock solution has a protein concentration of less than 100 fg/TCIDso. In one embodiment, the high purity virus or high purity virus stock solution has a protein concentration of less than 60 fg/TCID 50 . In another embodiment, the high purity virus or high purity virus stock solution has a DNA concentration of less than 50 fg/TCID 5 o. In one embodiment, the high purity virus or high purity virus stock solution has a DNA concentration of less than 15 fg/TCID 50 .
• the high purity virus or high purity virus stock solution has a protein concentration of less than 100 fg/TCID 50 and a DNA concentration of less than 50 fg/TCID 5 o. In one embodiment, the high purity virus or high purity virus stock solution has a protein concentration of less than 60 fg/TCID 5 o and a DNA concentration of less than 15 fg/TCID 5 o.
• the high purity virus or high purity virus stock solution has a virus concentration of at least 10 6 TCID 5 o/ml.
• a further embodiment of the invention is a method of evaluating and/or validating a virus clearance process and materials used therein. A scaled virus clearance process is tested using the test sample and analyzing the results of the virus clearance process. The amount of virus clearance evaluates and determines the validation of the virus clearance process and the materials used in the virus clearance process. If the virus is sufficiently removed from the test sample to meet regulatory standards, the virus clearance process and materials used in the clearance process are validated.
• the method of evaluating and/or validating a virus clearance process comprises spiking a sample with a high purity virus stock solution to produce a test sample.
• the high purity virus solution comprises a protein concentration of less than 100 fg/TCID 5 o, and a DNA concentration of less than 50 fg/TCIDso.
• Another embodiment of the invention is a method of evaluating and/or validating a virus clearance process in a method comprising spiking a sample with a virus solution, wherein the virus solution is prepared by a method comprising flow- through chromatography, a bead-based chromatography, size-exclusion processing, or hydrophobicity-based processing.
• the virus solution is prepared by cation exchange flow-through chromatography.
• the virus solution is prepared by anion exchange flow-through chromatography.
• the flow-through chromatography comprises cation exchange flow-through chromatography on a membrane or a bead-based matrix.
• the method of evaluating and/or validating a virus clearance process and materials used therein comprises spiking a sample with a high purity virus stock solution comprising at least 10 7 TCID 5 o/ml of virus, a protein concentration of less than 100 fg/TCID 5 o, and a DNA concentration of less than 50 fg/TCID 50 .
• FIG. 1 is a schematic outline of the generalized virus production protocol and an example of a specific minute virus of mice (MVM) production process.
• FIG. 2 is a flow chart demonstrating one embodiment of the invention.
• FIGS. 3A-3C illustrate one embodiment of the invention.
• FIG. 3 A is a silver-stained SDS-PAGE gel of samples taken at different stages in a sample virus preparation process. Lanes 1,14 and 15 are standard molecular weight markers. Lane 2 is a sample of the MVM infected cell media at day 3 immediately before the changing of the media from Dulbecco's Modified Eagle Medium (DMEM) with 1% fetal bovine serum (FBS) to serum-free DMEM. Lane 3 is a sample of pooled cell lysate at the completion of infection on day 14. Lane 4 is a sample of clarified lysate. Lane 5 is a sample of filtrate from Dulbecco's Modified Eagle Medium (DMEM) with 1% fetal bovine serum (FBS) to serum-free DMEM. Lane 3 is a sample of pooled cell lysate at the completion of infection on day 14. Lane 4 is a sample of clarified lysate. Lane 5 is a sample of filtrate from Dulbecco's Modified Eagle Medium (DMEM) with
• Lane 6 is a sample of diluted retentate from ultrafiltration for virus concentration.
• Lane 7 is a sample of supernatant after virus precipitation by ultracentrifugation.
• Lane 8 is a sample of the virus pellet after virus precipitation by ultracentrifugation.
• Lane 9 is a sample of the virus pellet after virus precipitation by ultracentrifugation and filtration through a 0.22 micron filter.
• Lanes 10 and 12 are samples of an early fraction of
• CEX cationic exchange
• PES poly ether sulphone
• FIG. 3B is adapted from Willwand et al, J Virol (1993) 67:5660
• MVM capsid proteins VPl is 83kDa and VP2 is 64kDa.
• the predominant two protein bands apparent by silver-stained SDS- PAGE in the final purified virus product (FIG. 3 A) are of the same size and in the same proportion as known MVM virus capsid proteins VPl and VP2, suggesting a very pure virus stock in which the major remaining proteins are viral rather than impurities.
• FIG. 3C is a table corresponding to the SDS-PAGE gel in FIG. 3 A with calculated MVM virus titers (log TCIDso/ml), protein concentrations (ug/ml and fg/TCID 50 ), and DNA concentrations (ug/ml and fg/TCID50) for each sample in lanes 2-13.
• FIG. 4 is a table demonstrating the reproducibility of the MVM production process described herein.
• FIGS. 5A-5B illustrate one embodiment of the invention.
• FIG. 5A is a table corresponding to the SDS-PAGE gel in FIG. 5B with calculated MVM virus titers (log TCID 50 /ml) and protein concentrations (ug/ml and fg/TCID50) for each sample in lanes 2-11.
• FIG. 5B is a silver-stained SDS-PAGE gel of samples taken at different stages in a sample virus preparation process.
• Lanes 1 and 12 are standard molecular weight markers.
• Lane 2 is a sample of the MVM infected cell media at day 3 immediately before the changing of the media from AdvancedTM DMEM with 1% FBS to serum-free AdvancedTM DMEM.
• Lane 3 is a sample of pooled cell lysate at the completion of infection on day 14.
• Lanes 4 and 5 are samples of clarified lysate.
• Lane 6 is a sample of filtrate from ultrafiltration (Centricon®) for virus
• Lane 7 is a sample of diluted retentate from ultrafiltration for virus concentration.
• Lane 8 is a sample of supernatant after virus precipitation by ultracentrifugation.
• Lane 9 is a sample of the virus pellet resuspended after virus precipitation by ultracentrifugation.
• Lane 10 is a sample of the third fraction of chromatographic polishing using CEX membrane adsorber.
• Lane 11 is a sample of the twenty-seventh fraction of chromatographic polishing using CEX membrane adsorber.
• FIG. 6 is a table of data for virus production of high titer and high purity, using the methods as described herein.
• FIG. 7 is a graph demonstrating hydraulic performance of a test filter
• V-Pro Viresolve® Pro (V-Pro) using a sample spiked with a virus prepared as described herein and compared with a sample spiked with a standard virus preparation typically used for validation studies, which was provided by a contract testing organization (CTO).
• the virus preparation by the CTO used an ultracentrifugation method.
• MVM prepared as described herein was spiked into a monoclonal antibody feed (9.1 g/L) that had previously presented filtration challenges due to interactions with virus spikes.
• MVM produced by the CTO spiked to a concentration of 2xl0 5 TCID 50 /ml resulted in a dramatic decrease in throughput across the filter V-Pro, compared to the unspiked feed baseline (no virus).
• the MVM prepared as described herein had no impact on hydraulic performance at a spike level of 5xl0 5 TCIDso/ml, nor did a ten-fold greater spike to 6xl0 6 TCID 50 /ml.
• FIG. 8 is a graph of three CTO MVM spiking stocks prepared by different methods evaluated for their hydraulic performance when spiked into a monoclonal antibody (Mab) feed and processed across Viresolve Pro.
• FIG. 9 is a photograph of an SDS-PAGE gel analysis of three standard CTO MVM preparations and an MVM preparation by the method of the present invention. Proteins in 4-15% gradient gel were visualized by silver stain. Each sample lane was loaded with ⁇ of sample. Lane 1 : Molecular weight markers; Lane 2: CTO crude MVM preparation (2.3xl0 7 TCID 50 /ml); Lane 3: CTO ultracentrifuge purified MVM preparation (1.8xl0 7 TCID 50 /ml); Lane 4 (2.3xl0 7 TCIDso/ml): CTO Q-membrane bind/elute purified MVM preparation; Lane 5:
• MVM preparation of the present invention (6.5x10 TCIDso/ml); Lane 6: Molecular weight markers.
• Contamination of biopharmaceutical products e.g., antibodies, recombinant proteins, vaccines, blood derivatives, plasma, and animal products, etc., by bacteria, viruses, prions, and the like, is a serious risk that needs to be sufficiently addressed.
• Contamination can arise by different ways. For example, it can occur because the source material (e.g., the cells in a cell culture, the blood product, etc.) is intrinsically contaminated with viruses.
• the manufacturing processes of biopharmaceutical products are also susceptible to virus contamination from extrinsic sources (e.g., inadvertent introduction from use of non-sterile or improperly sterilized materials).
• Virus clearance steps typically involve either virus removal steps or virus inactivation steps.
• Virus removal is a method in which the virus is physically removed from the sample. This is often achieved by either nanofiltration or chromatography.
• Nanofiltration techniques remove viruses by size exclusion.
• the success of chromatographic methods for removing viruses depends on the column composition and the reagents (e.g., buffers) used.
• virus inactivation is a method in which the viruses may remain in the final product, but in a non-infective (inactive) form. Many viruses contain lipid or protein coats that can be inactivated by chemical alteration. Alternatively, some viral inactivation processes denature the virus completely. Examples of virus inactivation methods include solvent and/or detergent inactivation, pasteurization (e.g., heating to high temperatures), pH mactivation (e.g., using an acidic pH), and irradiation (e.g., ultraviolet (UV) or gamma irradiation).
• solvent and/or detergent inactivation e.g., heating to high temperatures
• pH mactivation e.g., using an acidic pH
• irradiation e.g., ultraviolet (UV) or gamma irradiation
• Spiking studies use a scaled down model of the virus clearance step of a production-scale process to evaluating and/or validate the virus clearance steps and to evaluating and/or validate the apparatus used in the virus clearance method.
• the purity and titer of the virus stocks impact how well the scaled down model represents the production-scale process.
• Impurities e.g., DNA, RNA, protein, lipids, non-infectious particles and virus aggregates
• impurities can alter virus clearance rates by blocking the action of virus-inactivating chemicals, block effectiveness of radiation, alter binding to chromatographic media of target agents (e.g.,
• a test unit e.g., a filter or chromatography medium
• fouling e.g., blocking or clogging
• a test unit e.g., a filter or chromatography medium
• fouls prematurely, or exhibits altered fouling characteristics it ultimately reduces the passage of fluid through the virus filter.
• the actual throughput capacity of the filter is underestimated because such impurities are not normally present in the production-scale unit.
• the production-scale unit is oversized to compensate for the apparent lower performance of the unit in the validation study.
• Current industry standard methods of producing virus stocks e.g., for use in spiking studies
• virus stocks with high impurity content.
• virus stocks of as high a titer as possible are also desirable. This is in part because the volume of virus spike that can be added to a test system is limited by Regulatory Guidelines. The titer of the virus stock therefore determines the maximum possible concentration of virus spiked into the test material. As a result, the actual capacity of the test unit to clear virus in the production process may be underestimated. Current methods lack the capacity to produce virus stocks of high purity and high titer.
• virus preparation methods described herein produce virus of
• viruses for use in virus clearance studies and which can be produced in high titer and with high purity using the methods described herein include mammalian viruses and bacteriophages, for example and without limitation: RNA enveloped viruses (e.g., retroviruses such as human immunodeficiency virus- 1 (HIV-1), human immunodeficiency virus-2 (HIV-2), simian immunodeficiency virus (SIV), xenotropic, amphotropic, and ecotropic recombinant murine retroviruses, such as xenotropic murine leukemia virus (X-MuLV), visna virus; flaviviruses such as bovine viral diarrhea virus (BVDV); rhabdo viruses such as vesicular stomatitis virus (VSV); paramyxoviruses such as parainfluenza type 3 (PIV3)); R A non- enveloped viruses (e.g., reo viruses such as reovirus type 3 (reo-3); picornaviruses such
• polyomavirus such as simian virus 40 (SV40), and parvovirus, such as porcine parvovirus (PPV), canine parvovirus (CPV), parvovirus B19, and minute virus of mice (MVM) (also known as mice minute virus, murine minute virus, MMV)); and bacteriophage such as Phi-X 174 (or Phi-X), pseudomonas phage PP7,
• SV40 simian virus 40
• parvovirus such as porcine parvovirus (PPV), canine parvovirus (CPV), parvovirus B19, and minute virus of mice (MVM) (also known as mice minute virus, murine minute virus, MMV)
• bacteriophage such as Phi-X 174 (or Phi-X), pseudomonas phage PP7,
• enterobacteria phage PR772 enterobacteria phage PR772, and pseudomonas phage Phi-6.
• MVM minute virus of mice
• Virus clearance is calculated by comparing the viral load of the spiked starting material with the post-processing material obtained from the test unit to obtain the viral reduction factor (also referred to herein as the "virus reduction factor" or "VRF").
• FIG. 1 The generalized procedure for virus production of high purity and high titer, as well as a specific virus purification technique used for MVM, are schematically represented in FIG. 1.
• a "high purity virus” is a virus which has a very low impurity (e.g., protein, DNA, lipid) concentration.
• a high purity virus has a protein concentration of less than 50 ug/ml, less than 45 ug/ml, less than 40 ug/ml, less than 35 ug/ml, less than 30 ug/ml, less than 25 ug/ml, less than 20 ug/ml, less thanl 5 ug/ml, less than 10 ug/ml, less than 5 ug/ml, or less.
• the high purity virus or high purity virus stock solution has a protein concentration of less than 100 fg/TCIDso, less than 90 fg/TCID 50 , less than 80 fg/TCID 50 , less than 70 fg/TCID 50 , less than 60 fg/TCID 50 , less than 50 fg/TCID 50 , less than 40 fg/TCID 50 , less than 30 fg/TCID 50 , less than 20 fg/TCID 50 , less thanlO fg/TCID 50 , less than5 fg/TCID 50 , or less.
• the high purity virus or high purity virus stock solution has a DNA concentration of less than 50 fg/TCID 50; less than 45 fg/TCiD 50 , less than 40 fg/TCID 50l less than 35 fg/TCID 50 , less than 30 fg/TCID 50 , less than25 fg/TCIDso, less than 20 fg/TCID 50 , less thanl 5 fg/TCID 50 , less thanlO fg/TCID 50 , less than 5 fg/TCID 50 , less than 1 fg/TCID 50 , less than 0.5 fg/TCID 50 , or less.
• the high purity virus or high purity virus stock solution has a protein concentration as defined above and a DNA concentration as defined above. In one embodiment, the high purity virus or high purity virus stock solution has a protein concentration of less than 100 fg/TCID 50 and a DNA concentration of less than 50 fg/TCID 50 . In another embodiment, the high purity virus or high purity virus stock solution has a protein concentration of less than 60 fg/TCID 5 o and a DNA concentration of less than 15 fg/TCID 50 . In a further embodiment, the high purity virus or high purity virus stock solution has a protein concentration of less than 5 fg/TCID 5 o and a DNA concentration of less than 0.5 fg/TCIDso.
• TCID 50 /ml is a measurement of the amount of a pathogenic agent that will produce pathological change in 50% of cell cultures inoculated with the pathogenic agent, expressed as the "tissue culture infectious dose 50" (TCID50).
• tissue culture infectious dose 50 tissue culture infectious dose 50
• Techniques for determining TCID50 values are known in the art. In general, serial dilutions of a virus stock are prepared and inoculated onto replicate cell cultures, for example, in multi-well formats (e.g., 96 well plastic plates). The number of cell cultures that are infected is then determined for each virus dilution after a period of cell culture, typically by looking for cytopathic effect (CPE).
• CPE cytopathic effect
• the virus stock has a virus concentration of at least, or at least about, 10 5 TCID 50 /ml, 5xl0 5 TCID 50 /ml, 10 6 TCID 50 /ml, 5xl 0 6 TCID 50 /ml, 10 7 TCID 50 /ml, 5xl0 7 TCID 50 /ml, 10 8 TCID 50 /ml, 5xl0 8 TCID 50 /ml, 10 9 TCID 50 /ml, 5xl0 9 TCID 50 /ml, 10 10 TCID 50 /ml, 5xl0 10 TCID 50 /ml, 10 11 TCID 50 /ml, 5xl0 n TCID 5 o/ml, or more.
• the method comprises the sequential steps of obtaining a viral sample prepared under low protein conditions, concentrating the viral sample, changing to a suitable buffer, and precipitating the virus in the viral sample, such that the precipitated virus is a high purity virus.
• the high purity virus has a virus titer as described above.
• a viral sample prepared under low protein conditions can be achieved using any suitable method.
• the viral sample can be obtained from virus- infected cells cultured in low serum, serum-free, defined media culture, or a combination thereof.
• the cells are infected in a low serum containing cell culture medium (e.g., Dulbecco's Modified Eagle's Medium
• DMEM fetal bovine serum
• FBS fetal bovine serum
• the cells are infected in a serum-free cell culture media (e.g., DMEM without FBS, or Advanced DMEM without FBS), or defined serum-free cell culture media.
• the virus is concentrated and the cell media exchanged for a suitable buffer.
• a suitable buffer such as Tris-NaCl-EDTA (TNE) buffer (e.g., 10 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA); phosphate buffered saline (PBS) buffer (e.g., 137 mM NaCl, 2.7 mM KC1, 100 mM Na 2 HP0 4 , 2 mM KH 2 P0 4 , pH 7.4); Tris buffered saline (TBS) (e.g., 50 mM Tris, 150 mM NaCl, pH pH 7.6); Tris-EDTA (TE) buffer (e.g., lOmM Tris, lmM EDTA); or l OmM Tris.
• TNE Tris-NaCl-EDTA
• PBS phosphate buffered saline
• TBS Tris buffered s
• the viral sample is concentrated by ultrafiltration (e.g., an ultrafiltration centrifugal device), tangential flow filtration, dialysis, or a combination thereof.
• ultrafiltration the sample is processed through a membrane that passes the fluid and small molecules (e.g., salts, sugars, and proteins with a diameter less than the pore size of the membrane) but retains the virus.
• the fluid can be driven through the ultrafiltration membrane by a number of methods, including, but not limited to, centrifugation, peristaltic pumping, vacuum and air pressure.
• the virus is then resuspended into the desired volume of a new buffer.
• tangential flow filtration also known as cross flow filtration
• the feed solution flows perpendicular to the surface on an ultrafiltration membrane.
• a transmembrane pressure differential is created that causes fluid and small molecules to flow across the membrane while virus does not pass through, reducing the volume in the sample.
• the buffer can then be changed by feeding the new buffer into the tangential flow filtration system while continuing to draw fluid across the membrane.
• the sample is placed within a membrane sack that allows the free passage of fluid and small molecules but retains the virus in the interior.
• this "dialysis bag" into a large volume of buffer with a defined osmolarity, the cell culture media in the sample is diluted into the new buffer and the volume within the bag is reduced, achieving both buffer exchange and concentration of the virus.
• the viral sample is concentrated by ultrafiltration and buffer exchange to TNE.
• Precipitating the virus in the viral sample can be achieved by any suitable method. For example, ultracentrifugation, chemical-induced precipitation, chromatographic binding, polymer-induced aggregation, or a combination thereof. Ultracentrifugation techniques are standard in the art. For example, viral samples can be ultracentrifuged using standard devices at about 4°C, at least about 25,000 RPM (1 12600 x g), for at least about 4 hr and collected as a pellet at the bottom of the tube. A "cushion" of dense medium (e.g., glycerol) may be placed at the bottom of the tube before adding the sample so that the virus must pass through this dense layer to pellet at the bottom of the tube while impurities do not pass.
• dense medium e.g., glycerol
• Virus can also be centrifuged through a density gradient medium, such as cesium chloride or iodixanol, and the virus collected as a concentrated layer at some point along that density gradient.
• Virus precipitation using chemical agents can be any agent that binds the virus and forms insoluble aggregates (e.g., polyethylene glycol (PEG) of any suitable molecular weight (MW), such as about MW6,000 to about MWl 0,000).
• Chromatographic binding can be achieved by using a chromatographic medium that is suited to binding virus (e.g., Q- or S-type chemistry on agarose, controlled pore glass or membrane media).
• Soluble polymers that inducibly aggregate can also be used to precipitate virus in the virus sample (e.g., a smart polymer, such as polyethylene, polyvinyl chloride, polystyrene, polypropylene, and polyvinyl alcohol).
• a smart polymer such as polyethylene, polyvinyl chloride, polystyrene, polypropylene, and polyvinyl alcohol.
• the virus is precipitated by ultracentrifugation.
• the method further comprises chromatographic polishing of the precipitated virus.
• chromatographic polishing refers to removing trace impurities by passing the sample through a medium that retains impurities on the basis of their electrostatic charge or hydrophobicity, while the majority of virus passes through. Chromatographic polishing typically removes impurities not removed by virus precipitation.
• the virus is subjected to flow-through chromatographic polishing (e.g., using a cationic exchange (CEX) membrane adsorber, or an anionic exchange medium, such as ChromaSorbTM).
• CEX cationic exchange
• Such chromatographic polishing removes impurities such as proteins, nucleic acids, lipids, and sugars on the basis of their electrostatic charge from the viral sample.
• Other chromatographic polishing methods can be used, for example other membrane absorbers (e.g., Pall Mustang S); bead-based
• chromatographic media with appropriate chemistry S or Q depending on the virus and buffer conditions
• size-exclusion media size-exclusion media
• hydrophobicity-based media hydrophobicity-based media
• the virus flows through the chromatographic polishing media without binding while impurities bind the media, and are thus removed from the sample.
• the buffer conditions may be adjusted (e.g., to change salt content and/or the pH value) to maximize virus passage and impurity removal.
• MVM in TNE buffer, pH 7 is passed through a cationic exchange (CEX) membrane adsorber device, causing protein and DNA impurities to be adsorbed to the membrane and be removed while the majority of the virus passes through.
• CEX cationic exchange
• chromatographic polishing is applied to any method of virus preparation and purification to purify the virus and produce a high purity virus.
• other methods for virus preparation and purification in addition to those described herein, which can be further purified by chromatographic polishing include virus prepared by ultracentrifugation pelleting, gradient purification, ultrafiltration.
• Chromatographic polishing can also be used to purify virus from an unpurified virus preparation treated only by clarification to remove cellular debris.
• virus preparations may be purified, for example, in a flow- through mode using chromatographic media appropriate for the specific virus used, buffer conditions, and scale of the process.
• a virus e.g., MVM
• a virus concentrated by ultracentrifugation pelleting is passed through a cationic exchange (CEX) membrane.
• CEX membrane comprises AMPS (2- Acrylamido-2-methyl-l-propanesulfonic acid) crosslinked by MB Am ( ⁇ , ⁇ '- methylenebisacrylamide) on a poly ether sulphone (PES) matrix.
• Virus e.g., MVM
• total amount of impurities it is meant that the quantity of impurities is reduced (e.g., the number of micrograms or femto grams of impurities such as protein, DNA, and the like, is reduced by about 90 to about 99% as determined by standard assays, e.g., a bicinchoninic acid (BCA) assay for protein quantitation, PicoGreenTM for DNA quantitation, and the like).
• BCA bicinchoninic acid
• the number of impurities is significantly reduced.
• the protein impurities that are identifiable on a protein gel may be only a few different proteins (e.g., 2, 3, 5, 10, or 20), as opposed to hundreds, thousands, or tens of thousands of different proteins, as determined by methods such as silver staining of a protein SDS-PAGE gel.
• Impurities are virus preparation contaminants, such as DNA, RNA, protein, lipids, non-infectious particles and virus aggregates.
• the virus stock has a virus concentration of at least, or at least about, 10 5 TCIDso/ml, 5xl0 5 TCIDso/ml, 10 6 TCIDso/ml, 5xl0 6 TCIDso/ml, 10 7 TCIDso/ml, 5x10 7 TCIDso/ml, 10 8 TCIDso/ml, 5x10 8 TCIDso/ml, 10 9 TCIDso/ml, 5xl0 9 TCIDso/ml, 10 10 TCIDso/ml, 5xl0 10 TCIDso/ml, 10 11 TCIDso/ml, 5x10" TCID 5 o/ml, or more, and a protein concentration of less than, or less than about, lOOug/ml, 90ug/ml, 80ug/ml, 70ug/ml, 60ug/ml, 50ug/ml,
• the virus stock has a virus concentration of at least, or at least about, 10 5 TCIDso/ml, 5xl0 5 TCIDso/ml, 10 6 TCIDso/ml, 5xl0 6 TCIDso/ml, 10 7 TCIDso/ml, 5xl0 7 TCIDso/ml, 10 8 TCIDso/ml, 5xl0 8 TCIDso/ml, 10 9 TCIDso/ml, 5xl0 9 TCIDso/ml, 10 10 TCIDso/ml, 5xl0 10 TCIDso/ml, 10 11 TCIDso/ml, 5xl0 n TCIDso/ml, or more, and a protein concentration of less than, or less than about, 100fg/ TCIDso, 90fg/ TCIDso, 80fg/ TCID 50 , 70fg/ TCID 50 , 60
• the virus stock has a virus concentration of at least, or at least about, 10 5 TCIDso/ml, 5xl0 5 TCID 50 /ml, 10 6 TCID 50 /ml, 5xl0 6 TCID 50 /ml, 10 7 TCIDso/ml, 5xl0 7 TCID 50 /ml, 10 8 TCID 50 /ml, 5xl0 8 TCID 50 /ml, 10 9 TCID 50 /ml, 5xl0 9 TCIDso/ml, 10 10 TCID 50 /ml, 5xl0 10 TCID 50 /ml, 10 11 TCID 50 /ml, 5xlO n TCID 50 /ml, or more, and a DNA concentration of less than, or less than about, 30fg/ TCIDso, 25fg/ TCIDso, 20fg/ TCID 50 , 15fg/ TCID 50 , 10
• the virus stock has a virus concentration of at least, or at least about, 10 5 TCIDso/ml, 5x10 5 TCID 50 /ml, 10 6 TCIDso/ml, 5x10 6 TCID 50 /ml, 10 7 TCIDso/ml, 5xl0 7 TCIDso/ml, 10 8 TCIDso/ml, 5x10 8 TCIDso/ml, 10 9 TCID 50 /ml, 5xl0 9 TCIDso/ml, 10 10 TCID 50 /ml, 5xl0 10 TCIDso/ml, 10 11 TCIDso/ml, 5xlO n TCIDso/ml, or more; a protein concentration of less than, or less than about, lOOfg/ TCIDso, 90fg/ TCIDso, 80fg TCID 50 , 70fg/ TCID 50 , 60fg/
• the methods described herein can be applied to purifying many viruses to a concentration of at least, or at least about 10 6 TCID 50 /ml, 10 7 TCIDso/ml, 10 8 TCID 50 /ml, 10 9 TCID 50 /ml, 10 10
• TCID 5 o/ml 10 11 TCIDso/ml, 5xlO n TCIDso/ml, or more.
• a method of purifying a virus to a concentration of at least 10 6 TCIDso/ml comprising the sequential steps of obtaining a viral sample prepared under low protein conditions, concentrating the viral sample in a suitable buffer, and precipitating the virus in the viral sample, wherein the precipitated virus has a virus concentration of at least 10 7 TCIDso/ml, thereby purifying a virus to a concentration of at least 10 7 TCIDso/ml.
• the method purifies a virus to a concentration of at least, or at least about, 10 5 TCIDso/ml, 5x10 5 TCID 50 /ml, 10 6 TCIDso/ml, 5x10 6
• TCIDso/ml 10 7 TCID 50 /ml, 5xl0 7 TCIDso/ml, 10 8 TCIDso/ml, 5xl0 8 TCIDso/ml, 10 9 TCIDso/ml, 5x10 9 TCID 50 /ml, 10 10 TCID 50 /ml, 5x10 10 TCID 50 /ml, 10 11 TCID 50 /ml, 5x10 11 TCID 50 /ml, or more.
• the method purifies the virus to a concentration of at least, or at least about, 10 6 TCID 50 /ml, 5x10 6 TCID 50 /ml, 10 7 TCID 50 /ml, 5x10 7 TCID 50 /ml, 10 8 TCID 50 /ml, 5x10 8 TCID 50 /ml, 10 9 TCID 50 /ml, 5x10 9 TCID 50 /ml, 10 10 TCID 50 /ml, 5xl0 10 TCID 50 /ml, 10 11 TCID 50 /ml, 5xlO n TCID 50 /ml, or more, and a protein concentration of less than, or less than about, lOOug/ml, 90ug/ml, 80ug/ml, 70ug/ml, 60ug/ml, 50ug/ml, 40ug/ml, 30ug/ml, 20ug/ml, or less,
• the method purifies the virus to a concentration of at least, or at least about, 10 6 TCID 50 /ml, 5x10 6 TCID 50 /ml, 10 7 TCID 50 /ml, 5x10 7 TCIDjo/ml, 10 8 TCID 50 /ml, 5x10 8 TCID 50 /ml, 10 9 TCID 50 /ml, 5x10 9 TCID 50 /ml, 10 10 TCID 50 /ml, 5xl0 10 TCID 50 /ml, 10 11 TCID 50 /ml, 5xlO n TCID 50 /ml, or more, and a protein concentration of less than, or less than about, lOOfg/ TCID 5 o, 90fg/ TCIDso, 80fg/ TCID 50 , 70fg/ TCID 50 , 60fg/ TCID 50 , 50fg/ TCID 50 , 40fg/ TC
• the method purifies the virus to a concentration of at least, or at least about, 10 6 TCID 50 /ml, 5xl0 6 TCID 50 /ml, 10 7 TCID 50 /ml, 5xl0 7 TCIDso/ml, 10 8 TCID 50 /ml, 5xl0 8 TCID 50 /ml, 10 9 TCID 50 /ml, 5xl0 9 TCID 50 /ml, 10 10 TCID 50 /ml, 5xl0 10 TCID 50 /ml, 10 11 TCID 50 /ml, 5x10° TCID 50 /ml, or more, and a DNA concentration of less than, or less than about, 30fg/ TCIDso, 25fg/
• TCIDso 20fg/ TCIDso, 15fg TCID 50 , lOfg TCID 50 , 5fg/ TCID 50 , 1 fg/TCID 50 , 0.5 fg/TCIDso, or less.
• the method purifies the virus to a concentration of at least, or at least about, 10 6 TCID 50 /ml, 5x10 6 TCID 50 /ml, 10 7 TCID 50 /ml, 5x10 7 TCIDso/ml, 10 8 TCID 50 /ml, 5x10 8 TCID 50 /ml, 10 9 TCID 50 /ml, 5x10 9 TCID 50 /ml, 10 10 TCIDso/ml, 5xl0 10 TCID 5 o/ml, 10 11 TCID 50 /ml, 5xlO n TCID 50 /ml, or more; a protein concentration of less than, or less than about, lOOfg/ TCID 50 , 90fg/ TCID 50 , 80fg/ TCIDso, 70fg/ TCIDso, 60fg TCID 50 , 50fg TCID 50 , 40fg/ TCID50
• Another embodiment of the invention is a high purity virus or high purity virus stock produced by the methods described herein.
• a composition comprising, consisting essentially of, or consisting of, a high purity virus or high purity virus stock produced by the methods described herein.
• a further embodiment of the invention is a method of evaluating and/or validating a virus clearance process and the virus clearance unit operation used in the clearance process (e.g., a filter of flat membrane or hollow fiber type run in either direct flow or tangential flow modes; chromatographic steps including cationic exchange, anionic exchange, hydrophobic exchange, mixed-mode chromatography, affinity chromatography such as protein A or other ligand-based adsorption; virus inactivation process such as low pH, solvent/detergent, irradiation (gamma or ultraviolet), heat treatment).
• a virus clearance process e.g., a filter of flat membrane or hollow fiber type run in either direct flow or tangential flow modes
• chromatographic steps including cationic exchange, anionic exchange, hydrophobic exchange, mixed-mode chromatography, affinity chromatography such as protein A or other ligand-based adsorption
• virus inactivation process such as low pH, solvent/detergent, irradiation (gamma or ultraviolet), heat treatment).
• one method for evaluating and/or validating a virus clearance process is a virus spiking study in a scaled-down model of the virus clearance process (also referred to herein as a "scaled virus clearance process").
• the aim of the virus spiking study is to assess the effectiveness of a virus clearance unit in clearing viruses from the product (such as a biopharmaceutical) manufacturing processes. Higher virus titers allow larger virus reduction factors to be demonstrated and allow a more rigorous challenge to the virus clearance unit operation.
• Samples used in validating or evaluating a virus clearance process and/or a virus clearance unit used in a virus clearance process are any suitable samples of the manufacturing process feed.
• a suitable sample is representative of a product produced during the manufacture of a biopharmaceutical. Examples include sample solutions comprising antibodies, recombinant proteins, vaccines, conjugated proteins, blood derivatives, plasma, and animal products, etc.
• one embodiment is a method of evaluating and/or validating a virus clearance process, the method comprises spiking a sample with a high purity virus solution.
• the high purity virus solution has a protein
• the high purity virus stock solution has a virus concentration of at least, or at least about, 10 6 TCID 5 o/ml to at least, or at least about, 10 TCIDso/ml, or more of high purity virus.
• a scaled virus clearance process which is a scaled-down model of the virus clearance process, is tested using the test sample and analyzing the results of the virus clearance process, such that the amount of virus clearance evaluates and determines the validation of the virus clearance process.
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance process comprises a protein concentration of less than, or less than about, lOOug/ml, 90ug/ml, 80ug/ml, 70ug/ml, 60ug/ml, 50ug/ml, 40ug/ml, 30ug/ml, 20ug/ml, or less, protein.
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance process comprises a protein concentration of less than, or less than about, 100fg/ TCID 50 , 90fg/ TCID 50 , 80fg/ TCID 50 , 70fg/ TCID 50 , 60fg TCID 50 , 50fg/ TCIDso, 40fg/ TCID50, 30fg/ TCID 50 , 20fg/ TCID 50 , 15fg/ TCID 50 , 10fg/ TCID 50 , 5fg/ TCID50, or less.
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance process comprises a DNA concentration of less than, or less than about, 30fg/ TCID 50 , 25fg/ TCID 50 , 20fg/ TCID50, 15fg/ TCID 50 , 10fg/ TCID50, 5fg/ TCID 50 , 1 fg/TCID 50 , 0.5 fg/TCID 50 , or less.
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance process comprises at least, or at least about, 10 6 TCID 50 /ml, 5x10 6 TCID 50 /ml, 10 7 TCID 50 /ml, 5x10 7 TCID 50 /ml, 10 8 TCID 50 /ml, 5x10 8 TCID 50 /ml, 10 9 TCID 50 /ml, 5x10 9 TCID 50 /ml, 10 10 TCID 50 /ml, 5xl0 10 TCID 50 /ml, 10 11 TCID 50 /ml, 5xl0 u TCID 50 /ml, or more virus.
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance process comprises at least, or at least about, 10 5 TCIDso/ml, 5x10 5 TCID 50 /ml, 10 6 TCID 50 /ml, 5x10 6 TCID 50 /ml, 10 7 TCID 50 /ml, 5xl0 7 TCID 50 /ml, 10 8 TCID 50 /ml, 5x10 s TCID 50 /ml, 10 9 TCID 50 /ml, 5xl0 9 TCIDso/ml, 10 10 TCID 50 /ml, 5xl0 10 TCID 50 /ml, 10 11 TCID 50 /ml, 5xlO n TCIDso/ml, or more virus, and a protein concentration of less than, or less than about, lOOug/ml, 90ug/ml, 80ug/ml, 70ug/
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance process comprises at least, or at least about, 10 5 TCID 50 /ml, 5x10 5 TCID 50 /ml, 10 6 TCID 50 /ml, 5xl0 6 TCID 50 /ml, 10 7 TCIDso ml, 5x10 7 TCIDso/ml, 10 8 TCIDso/ml, 5x10 8 TCIDso/ml, 10 9 TCIDso/ml, 5xl0 9 TCIDso/ml, 10 10 TCIDso/ml, 5xl0 10 TCIDso/ml, 10 11 TCIDso/ml, 5xlO n TCIDso/ml, or more virus, and a protein concentration of less than, or less than about, lOOfg/ TCIDso, 90fg/ TCID 50 , 80fg/ TC
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance process comprises at least, or at least about, 10 5 TCIDso/ml, 5x10 5 TCIDso/ml, 10 6 TCID 50 /ml, 5x10 6 TCIDso/ml, 10 7 TCIDso/ml, 5x10 7 TCIDso/ml, 10 8 TCIDso/ml, 5x10 8 TCIDso/ml, 10 9 TCIDso/ml, 5xl0 9 TCIDso/ml, 10 10 TCIDso/ml, 5xl0 10 TCIDso/ml, 10 11 TCIDso/ml, 5xlO n
• TCID 50 /ml, or more virus and a DNA concentration of less than, or less than about, 30fg/ TCIDso, 25fg/ TCID 50 , 20fg/ TCID 50 , 15fg/ TCID 50 , 10fg/ TCID 50 , 5fg/ TCIDso, 1 fg/TCIDso, 0.5 fg/TCID 50 , or less.
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance process comprises at least, or at least about, 10 5 TCIDso/ml, 5x10 5 TCIDso/ml, 10 6 TCIDso/ml, 5x10 6 TCIDso/ml, 10 7 TCIDso/ml, 5xl0 7 TCIDso/ml, 10 8 TCIDso/ml, 5xl0 8 TCIDso/ml, 10 9 TCIDso/ml, 5xl0 9 TCIDso/ml, 10 10 TCIDso/ml, 5xl0 10 TCIDso/ml, 10 11 TCIDso/ml, 5xlO n TCIDso/ml, or more virus; a protein concentration of less than, or less than about, 1 OOfg/ TCIDso, 90fg/ TCIDso, 80fg/ TC
• the test sample is spiked with at least, or at least about, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.1%, 0.01%, 0.001%, 0.0001% (vol/vol) of any one of the high purity virus solutions above.
• the test sample is spiked with at least, or at least about 10 5 TCID 50 /ml, 5x10 5 TCID 50 /ml, 10 6
• TCIDso/ml 5x10 6 TCID 50 /ml, 10 7 TCID 50 /ml, 5x10 7 TCID 50 /ml, 10 8 TCID 50 /ml, 5xl0 8 TCIDso/ml, 10 9 TCID 50 /ml, 5xl0 9 TCID 50 /ml, 10 10 TCID 50 /ml, 5xl0 10 TCiD 50 /ml, 10 11 TCID 5 o/ml, 5x10* 1 TCID 50 /ml, or more virus from any one of the high purity virus solutions above.
• the scaled virus clearance process comprises a filter.
• a further embodiment is a method of evaluating and/or validating a virus clearance unit.
• the method comprises spiking a sample with a high purity virus solution as described above.
• the high purity virus comprises a protein concentration of less than 100 fg/TCID 50 , and a DNA concentration of less than 50 fg/TCID 5 o, to produce a test sample.
• the high purity virus solution comprises at least, or at least about, 10 6 TCIDso/ml of virus to at least, or at least about, 10 7 TCIDso/ml of virus, or more.
• a virus clearance unit which is a scaled-down model of the virus clearance unit used in a virus clearance process, is tested using the test sample and analyzing the results of the virus clearance unit, such that the amount of virus clearance determines the effectiveness of the virus clearance unit.
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance unit comprises a protein concentration of less than, or less than about, lOOug/ml, 90ug/ml, 80ug/ml, 70ug/ml, 60ug/ml, 50ug/ml, 40ug/ml, 30ug/ml, 20ug/ml, or less, protein.
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance unit comprises a protein concentration of less than, or less than about, lOOfg/ TCIDso, 90fg/ TCIDso, 80fg/ TCID 50 , 70fg/ TCID 50 , 60fg/ TCID 50 , 50fg/ TCIDso, 40fg/ TCIDso, 30fg/ TCID 50 , 20fg/ TCID 50 , 15fg TCID 50 , 10fg/ TCID 50 , 5fg/ TCID 50 , or less.
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance unit comprises a DNA concentration of less than, or less than about, 30fg/ TCID 50 , 25fg/ TCID 50 , 20fg/ TCID50, 15fg/ TCID50, 10fg/ TCID50, 5fg/ TCID50, 1 fg/TCID 50 , 0.5 fg/TCID 50 , or less.
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance unit comprises at least, or at least about, 10 6 TCIDso/ml, 5x10 6 TCID 50 /ml, 10 7 TCID 50 /ml, 5x10 7 TCID 50 /ml, 10 8 TCID 50 /ml, 5x10 8 TCID 50 /ml, 10 9 TCID 50 /ml, 5x10 9 TCID 50 /ml, 10 10 TCID 50 /ml, 5xl0 10 TCID 50 /ml, 10 11 TCID 50 /ml, or more virus.
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance unit comprises at least, or at least about, 10 5 TCIDso/ml, 5x10 5 TCID 50 /ml, 10 6 TCID 50 /ml, 5x10 6 TCID 50 /ml, 10 7 TCID 50 /ml, 5xl0 7 TCID 50 /ml, 10 8 TCID 50 /ml, 5xl0 8 TCID 50 /ml, 10 9 TCID 50 /ml, 5xl0 9 TCID 50 /ml, 10 10 TCID 50 /ml, 5xl0 10 TCID 50 /ml, 10 11 TCID 50 /ml, 5xlO n TCID 5 o/ml, or more virus, and a protein concentration of less than, or less than about, lOOug/ml, 90ug/ml, 80ug/ml, 70ug
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance unit comprises at least, or at least about, 10 5 TCIDso/ml, 5x10 5 TCID 50 /ml, 10 6 TCID 50 /ml, 5x10 6 TCID 50 /ml, 10 7 TCIDso/ml, 5xl0 7 TCID 50 /ml, 10 8 TCID 50 /ml, 5xl0 8 TCID 50 /ml, 10 9 TCID 50 /ml, 5xl0 9 TCID 50 /ml, iO 10 TCID 50 /ml, 5xl0 10 TCID 50 /ml, 10 11 TCID 50 /ml, 5xl0 n TCID 5 o/ml, or more virus, and a protein concentration of less than, or less than about, 100fg/ TCID50, 90fg/ TCID50, 80fg/ TC
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance unit comprises at least, or at least about, 10 5 TCIDso/ml, 5x10 5 TCID 50 /ml, 10 6 TCID 50 /ml, 5xl0 6 TCID 50 /ml, 10 7 TCIDso/ml, 5x10 7 TCIDso/ml, 10 8 TCID 50 /ml, 5x10 8 TCID 50 /ml, 10 9 TCID 50 /ml, 5xl0 9 TCIDso/ml, 10 10 TCID 50 /ml, 5xl0 10 TCID 50 /ml, 10 11 TCID 50 /ml, 5xlO n
• TCIDso/ml or more virus, and a DNA concentration of less than, or less than about, 30fg/ TCIDso, 25fg/ TCID 50 , 20fg/ TCID50, 15fg TCID 50 , 10fg TCID 50 , 5fg/ TCIDso, 1 fg/TCIDso, 0.5 fg/TCID 50 , or less.
• the high purity virus solution used in a method of evaluating and/or validating a virus clearance unit comprises at least, or at least about, 10 5 TCIDso/ml, 5x10 5 TCID 50 /ml, 10 6 TCIDso/ml, 5xl 0 6 TCIDso/ml, 10 7 TCIDso/ml, 5xl0 7 TCIDso/ml, 10 8 TCIDso/ml, 5xl0 8 TCID 50 /ml, 10 9 TCID 50 /ml, 5xl0 9 TCIDso/ml, 10 10 TCID 50 /ml, 5xl0 10 TCID 50 /ml, 10 11 TCID 50 /ml, 5xl0 n TCIDso/ml, or more virus; a protein concentration of less than, or less than about, 1 OOfg/ TCIDso, 90fg/ TCID 50 , 80fg/
• the test sample is spiked with at least, or at least about, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% (vol/vol) of any one of the high purity virus solutions above.
• the test sample is spiked with at least, or at least about 10 5 TCIDso ml, 5x10 5 TCIDso/ml, 10 6 TCIDso/ml, 5x10 6 TCIDso/ml, 10 7 TCIDso/ml, 5xl0 7 TCIDso/ml, 10 8 TCIDso/ml, 5xl0 8 TCIDso/ml, 10 9 TCIDso/ml, 5xl0 9 TCIDso/ml, 10 10 TCID 50 /ml, 5xl 0 10 TCIDso/ml, 10 11 TCID 50 /ml, 5xl0 n TCIDso/ml, or more virus from any one of the high purity virus solutions above.
• the virus clearance unit is validated.
• the virus clearance unit comprises a filter. The virus removal achieved in a comprehensive scaled-down viral clearance study may be added to the viral clearance claims reported in drug application regulatory filing.
• Example 1 MVM Propagation with 324K cells (see FIGS. 2-4)
• Propagation cell line 324K cells (Simian virus 40-transformed human fibroblasts), freshly thawed from stock.
• Mouse minute virus (MVM) derived from an ATCC (catalog #VR-1346) virus stock was used to infect 324K host cells.
• Resuspension buffer 10 mM Tris [pH 8.0], 150 mM NaCl, 1 mM EDTA).
• Millipore cationic exchange (CEX) membrane adsorber comprising AMPS (2-Acrylamido-2-methyl-l-propanesulfonic acid) crosslinked by MB Am ( ⁇ , ⁇ '-methylenebisacrylamide) on a polyethersulphone (PES) matrix, Millipore Centricon®-70 1 OOkDa centrifugal ultrafiltration devices, and Millipore MillexTM Durapore 0.22 ⁇ filters.
• CEX Millipore cationic exchange
• Assays were carried out at multiple stages in the virus stock preparation methods described herein. In this example, assays were carried out at the points indicated in red in FIG. 2.
• the assay panel for each sample was as follows: virus titer (see below), BCA protein content (not on pre-Centricon® samples),
• 324K host cell line growth Thirty Tl 50 flasks of 324K cells were grown to confluency from a freshly thawed working stock vial. Media for growth: DMEM with 10% FBS.
• Counted cell density 2.7E+05 cells/ml.
• MVM stock titer 1x108
• Clarification Centrifuge lysate by spinning at 2000 x g for 15 minutes. Decant and save supernatants (discard pellets). Filter supernatant with 0.22 ⁇ GP Express Plus (PVDF) Stericups. Total clarified lysate volume: 532.6 ml
• Centricon®Plus 100 kDa devices with 70ml clarified lysate each 280ml total.
• Spin Centricon® tubes until retentate volume 1-2 ml (Thermo Fisher tabletop centrifuge, rotor: 228, temp: 4°C, speed: 2390 x g, total Spin Time (Spin 1): 13min). Save the filtrate in common filtrate pool.
• Spin Centricon® tubes again as above until retentate volume 1-2 ml.
• Total Spin Time (Spin 2): 16.45 min. Combine filtrate with previous filtrate from previous spin.
• Assay Centricon® filtrate (to detect any virus breakthrough and to visualize/quantitate proteins and DNA removed by Centricon® process). Set aside any remaining clarified lysate.
• Ultracentrifugation Weigh a 30ml ultracentrifuge tube with cap. Empty tube weight: 86.638 g. Bring retentate pool volume up to 31ml using TNE (so that ultracentrifuge tube will be full when capped after removing 1 ml for assays). Assay diluted retentate. The expected virus concentration factor at this point is 18X from clarified lysate. Transfer diluted retentate pool to the 30ml ultracentrifuge tube. Add TNE if needed to completely fill tube. Weigh filled, capped ultracentrifuge tube. Filled tube weight: 115.692 g. Total diluted retentate volume (filled - empty weight): 29.054 ml.
• Prechill ultracentrifuge to 4°C. Make a balance tube of same weight as virus tube.
• Ultracentrifuge virus (Ultracentrifuge rotor: SW28, Temp: 4°C, Speed: 25,000 RPM (1 12600 x g), Time: 4 hr). Carefully decant supernatants from tube. Assay supernatant. Resuspend pellet in 15ml TNE by pipetting up and down. Collect resuspended virus into new tube. Rinse ultracentrifuge tube with another 15ml of TNE by pipetting up and down. Combine rinse with first pellet resuspension to form a 30ml pool of virus. Assay resuspended pellet pool.
• Sterile Filtration Sterile filter using 0.22 ⁇ Durapore Millex syringe filters. Assay ⁇ 8 ⁇ -0.22 ⁇ filtrates.
• CEX membrane adsorber processing Pass 30ml virus pool through CEX membrane absorber device.
• CEX procedure Pre-wet CEX device at 30 psi for 10 minutes with MilliQ. Repeat device pre-wet with buffer. After pre-wet, remove device from pressure source and attach hydrophobic Millex to V-Shield vent. Using a sterile syringe, slowly expel remaining volume in the CEX device. Be careful not to apply full pressure to device, some liquid should remain between membrane layers. Using a syringe pump, set syringe diameter and flow rate (2mL/min). Load syringe with virus prep and remove all air from syringe.
• Virus storage Snap-freeze vials by dipping in isopropanol/dry ice bath.
• 324K cells produced ⁇ 7.7 log TCID 5 o/ml in the raw lysate. Removal of serum did not decrease titers from those previously seen in FBS-containing preps. Centricon® allowed for recovery of most of the virus, but did not remove contaminating proteins. Centrifugation recovered most of the remaining virus, with a considerable increase in purity. Passage of resuspended pellet across Millipore CEX membrane adsorber removed most of the remaining contaminants. Consistent results found for evaluation runs 1-4, which were all performed using this method.
• Example 2 MVM Propagation with A9 cells (see FIGS. 5-7)
• Example 1 The method of Example 1 was repeated with the substitution of A9 cells
• A9 cells produced 9.75 log TCID 50 /ml in the raw cell lysate. Increased titer in the harvest led to a final virus stock with a concentration of 10.5 log TCID 50 /ml. SDS-PAGE showed that the virus harvests from the A9 propagation had more protein than the 324K lysates. However, despite the appearance of more protein in the final virus stock (these may be viral proteins), the final purity as measured by protein/infectious virus was ⁇ 2-5 fg protein/TCID 50 . Given that the media is still serum-free and the cell protein background would be expected to be equivalent, these may be viral proteins (and thus a consequence of the greater virus titer).
• Example 3 Evaluation of different standard CTO spiking stock solutions on hydraulic performance (see FIGS. 8-9).
• CTO MVM spiking stocks prepared by different methods were evaluated for their hydraulic performance when spiked into a monoclonal antibody (Mab) feed and processed across Viresolve Pro.
• the crude preparation was only clarified to remove cell debris and subjected to no further purification.
• the ultracentrifuged preparation was purified by pelleting the virus in infected cell culture lysate by ultracentrifugation, discarding the supernatant, and then resuspending the virus in PBS.
• the membrane bind/elute purified preparation was made by passing clarified, infected cell culture lysate across a membrane adsorber with positively charged Q chemistry. The virus bound to the membrane, and was then eluted with a phosphate buffer containing 400mM NaCl.
• MVM preparations made by the ultracentrifugation and membrane bind/elute purified methods are sold by the CTO to customers for use in their spiking studies.
• the targeted spike level for all three stocks was 1.4xl0 5 TCID 50 /ml. Each condition was run in duplicate (run #1 and run #2).
• the actual titers achieved in the feed post-spike were crude: 2x10 5 TCID 50 /ml; ultracentrifuged: 4x10 4 TCID 50 /ml; and membrane bind/elute purified: 6x10 4 TCID 50 /ml.
• the hydraulic performance of the membrane bind/elute purified preparation was no better than that of unpurified crude virus.
• the ultracentrifuged preparation had the best performance of the three CTO preparations, with throughput similar to that of unspiked feed (at the spike level of 4x10 4 TCIDso/ml).
• the virus preparations of the present invention performed significantly better than the CTO virus preparations (see, e.g., FIG. 7).
• Table 5 Summary of the biomolecular characterization of standard CTO MVM virus stock preparations (ultracentrifuge preparation and Q-membrane preparation) vs. MVM virus stock preparation by the method of the present invention.
• Protein was quantified by Micro BCA assay. *n.d. Not determined. Media components present in the crude virus stock interfere with the Micro BCA protein assay. DNA was quantified by PicoGreen® assay. As can be seen in Table 5, the CTO virus preparations have significantly more protein and DNA content.
• FIG. 9 is a photograph of a silver stained 4-15% gradient SDS-PAGE gel. Each sample lane was loaded with ⁇ of sample. Lane 1 :
• TCID 50 /ml CTO ultracentrifuge-purified MVM preparation (1.8xl0 7 TCID5o/ml); Lane 4: CTO Q-membrane bind/elute-purified MVM preparation (2.3x10 TCID 50 /ml); Lane 5: MVM preparation using the methods of the present invention (6.5x10 TCIDso/ml); Lane 6: Molecular weight markers.
• each of the CTO virus preparations have considerable total numbers of proteins present (see number of bands of proteins and smear of proteins in each lane), as well as total amount of protein per sample (demonstrated as total staining amount).
• the method of the present invention produces a virus preparation with minimal protein content, both quantitatively and qualitatively, as described herein.
• Example 4 Comparison of various cationic exchange media used for flow- through MVM virus stock purification.
• MVM virus stock (previously purified by buffer exchange into TNE and ultracentrifugation) was passed through various cationic exchange media. The flow- through material was then assayed for virus titer and protein content by MicroBCA assay following the manufacturer's protocol. The devices listed in Table 6 all removed significant amount of protein impurities while maintaining the titer of the virus preparation.
• Millipore CEX membrane adsorber comprising AMPS (2- Acrylamido-2-methyl-l-propanesulfonic acid) crosslinked by MBAm ( ⁇ , ⁇ '- methylenebisacrylamide) on a poly ether sulphone (PES) matrix
• Sartobind S15 (Sartorius) are both cation exchange membrane adsorbers.
• Pro Res-S (Millipore) is a monodispersed polymethacrylate strong cation exchange resin.
• Example 5 MVM stocks in a variety of buffers treated using a cationic exchange (CEX) membrane adsorber.
• MVM stocks in a variety of buffers were treated using a cationic exchange (CEX) membrane adsorber comprising AMPS (2-Acrylamido-2-methyl-l- propanesulfonic acid) cross-linked by MB Am ( ⁇ , ⁇ ' -methyl enebisacrylamide) on a poly ether sulphone (PES) matrix in a flow-through mode.
• CEX cationic exchange
• PES poly ether sulphone
• Table 7 MVM stocks in a variety of buffers treated using a cationic exchange (CEX) membrane adsorber.
• CEX cationic exchange

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Wood Science & Technology (AREA)
• Virology (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Biomedical Technology (AREA)
• Medicinal Chemistry (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Immunology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (3)

Family

ID=44148425

Family Applications (1)

Country Status (9)

Cited By (6)

Families Citing this family (16)

Family Cites Families (101)

• 2011
  • 2011-04-08 BR BR112012026095A patent/BR112012026095A2/pt not_active IP Right Cessation
  • 2011-04-08 WO PCT/US2011/031747 patent/WO2011130119A2/en not_active Ceased
  • 2011-04-08 KR KR1020127029690A patent/KR101549296B1/ko not_active Expired - Fee Related
  • 2011-04-08 US US13/082,828 patent/US9644187B2/en not_active Expired - Fee Related
  • 2011-04-08 SG SG2012075875A patent/SG184833A1/en unknown
  • 2011-04-08 CN CN201180018931.9A patent/CN102985536B/zh not_active Expired - Fee Related
  • 2011-04-08 JP JP2013504963A patent/JP2013523175A/ja active Pending
  • 2011-04-14 EP EP11162488.8A patent/EP2377927B1/en not_active Revoked
  • 2011-04-14 ES ES11162488T patent/ES2736166T3/es active Active
• 2015
  • 2015-04-10 JP JP2015081173A patent/JP6284500B2/ja not_active Expired - Fee Related
• 2017
  • 2017-07-07 JP JP2017134066A patent/JP6522054B2/ja not_active Expired - Fee Related

Also Published As

Similar Documents

Legal Events